[Moving irradiation in the combined radiation treatment of cervical cancer].
Application of moving telegamma therapy as an adjunct to the associated radiation treatment in 399 patients allowed an increase of the dosage up to 6500 rad in the parametrium area. A 5-year survival in stage I was 91.6 +/- 10.5%, in stage II--63.3 +/- 4.7% and in stage III--48 +/- 5.6%. Late postirradiation rectitis was noted in 24 patients, cystitis--in 8 and rectal fistula--in 7.
D001773:Blood Cells / Q000528:radiation effects; D005260:Female; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D011867:Radioisotope Teletherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy*
Podvizhnoe obluchenie pri sochetannom luchevom lechenii raka sheĭki matki.